FDA approves neladalkib for ALK-positive lung cancer - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

FDA approves neladalkib for ALK-positive lung cancer

  • By

  • Teraya Smith

  • November 18, 2026

  • 2 min

Share

  • 1

    The FDA granted accelerated approval to neladalkib for adults with locally advanced or metastatic ALK-positive NSCLC after specified prior targeted therapy.

  • 2

    Eligible patients had received alectinib as their only prior ALK TKI in the advanced setting or at least 2 ALK TKIs and platinum-based chemotherapy.

  • 3

    In ALKOVE-1, the confirmed overall response rate was 49% among 67 patients previously treated only with alectinib and 32% among 155 patients in the other treatment group.

  • 4

    Among responders, 76% and 52% in the alectinib-only group maintained responses for at least 6 and 12 months, respectively; corresponding rates in the other group were 69% and 51%.

  • 5

    Neladalkib is taken orally at 150 mg once daily; warnings include hepatotoxicity, renal and ocular toxicity, elevated creatine phosphokinase, and embryo-fetal toxicity.

Original Source(s)

Related Content